Company news
Rezolute, Inc. news in 2023
Rezolute, Inc.'s news releases, calls and decks from 2023, newest first.
Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism
December 13, 2023
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)
December 12, 2023
Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day
November 16, 2023
Rezolute Reports First Quarter Fiscal 2024 Results
November 12, 2023
Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism
October 16, 2023
Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism
October 10, 2023
Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress
September 13, 2023
Rezolute to Participate in Upcoming Investor Conferences in September
September 5, 2023
Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism
June 26, 2023
Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress
May 10, 2023
Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema
March 22, 2023
Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert
March 7, 2023
Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress
February 9, 2023